In 1986, IFN-α2 was approved to cure hairy cell leukemia, and it was developed as the first immunotherapy for adjuvant treatment of stage IIB/III melanoma in the USA in 1995 [7]. Here, IFNA2 is linked to hairy cell leukemia.